Non‑Small Cell Lung Cancer | Emerging Role of Antibody‑Drug Conjugates in the Management of Non‑Small Cell Lung Cancer

Featuring perspectives from Drs Alexander Spira and Helena Yu, including the following topics: Introduction  What is an antibody-drug conjugate? (0:00) “HER2-Positive” Non-Small Cell Lung Cancer (NSCLC)  Case: A woman in her mid 50s with HER2 insertion in exon 20 — Dr Yu (8:42) Targeting HER3 in NSCLC  Case: A man in his early 60s with lung cancer with an EGFR mutation — Dr Yu (25:23) TROP2-Directed Treatment  Case: A woman in her early 50s with lung cancer with a KRAS G12V mutation — Dr Spira (36:57) Case: A woman in her mid 60s with metastatic NSCLC and an EGFR exon 19 deletion — Dr Spira (39:32) Novel Agents  Mechanism of action of tusamitamab ravtansine and telisotuzumab vedotin (54:15) CME information and select publications